Adicet Bio, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Adicet Bio, Inc. (ACET) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 71.63 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-05
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 23.41K shares, a 96.23% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 48.22K shares, a 95.98% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was -2.22M shares, a 374.75% decline year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 910.46K shares, a 16.60% increase year-over-year.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 510.76K shares, a 72.75% decline from fiscal 2024.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 1.87M shares, a 68.52% increase from fiscal 2023.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 1.11M shares, a 366.18% increase from fiscal 2022.
- Adicet Bio, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 238.62K shares, a 72.50% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 23.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 71.63K shares 10-Q · filed 2026-08-05 | -2.15M shares derived: sum of 3 quarters · filed 2026-08-05 | -1.24M shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 48.22K shares 10-Q · filed 2026-05-13 | -2.17M shares derived: sum of 2 quarters · filed 2026-05-13 | -1.26M shares derived: sum of 3 quarters · filed 2026-05-13 | -640.67K shares derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | -2.22M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -1.31M shares derived: sum of 2 quarters · filed 2026-03-12 | -688.89K shares derived: sum of 3 quarters · filed 2026-03-12 | 510.76K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 910.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | 1.53M shares derived: sum of 2 quarters · filed 2025-11-05 | 2.73M shares 10-Q · filed 2025-11-05 | 3.54M shares derived: sum of 4 quarters · filed 2025-11-05 |
| 2025-06-30 | 621.07K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 1.82M shares 10-Q · filed 2025-08-07 | 2.63M shares derived: sum of 3 quarters · filed 2025-08-07 | 3.41M shares derived: sum of 4 quarters · filed 2025-08-07 |
| 2025-03-31 | 1.20M shares 10-Q · filed 2025-05-06 | 2.01M shares derived: sum of 2 quarters · filed 2025-05-06 | 2.79M shares derived: sum of 3 quarters · filed 2025-05-06 | 2.93M shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 808.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 1.59M shares derived: sum of 2 quarters · filed 2025-03-06 | 1.73M shares derived: sum of 3 quarters · filed 2025-03-06 | 1.87M shares 10-K · filed 2025-03-06 |
| 2024-09-30 | 780.84K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 919.25K shares derived: sum of 2 quarters · filed 2024-11-06 | 1.07M shares 10-Q · filed 2024-11-06 | 1.56M shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 138.41K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 285.61K shares 10-Q · filed 2024-08-13 | 778.20K shares derived: sum of 3 quarters · filed 2024-08-13 | 973.78K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 147.20K shares 10-Q · filed 2024-05-14 | 639.79K shares derived: sum of 2 quarters · filed 2024-05-14 | 835.37K shares derived: sum of 3 quarters · filed 2024-05-14 | 1.08M shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 492.59K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | 688.17K shares derived: sum of 2 quarters · filed 2024-03-19 | 934.30K shares derived: sum of 3 quarters · filed 2024-03-19 | 1.11M shares 10-K · filed 2024-03-19 |
| 2023-09-30 | 195.58K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | 441.71K shares derived: sum of 2 quarters · filed 2023-11-08 | 619.82K shares 10-Q · filed 2023-11-08 | 676.93K shares derived: sum of 4 quarters · filed 2023-11-08 |
| 2023-06-30 | 246.13K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 424.24K shares 10-Q · filed 2023-08-09 | 481.36K shares derived: sum of 3 quarters · filed 2023-08-09 | 570.84K shares derived: sum of 4 quarters · filed 2023-08-09 |
| 2023-03-31 | 178.11K shares 10-Q · filed 2023-05-09 | 235.23K shares derived: sum of 2 quarters · filed 2023-05-09 | 324.71K shares derived: sum of 3 quarters · filed 2023-05-09 | 372.66K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 57.12K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 146.60K shares derived: sum of 2 quarters · filed 2023-03-15 | 194.55K shares derived: sum of 3 quarters · filed 2023-03-15 | 238.62K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 89.49K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 137.43K shares derived: sum of 2 quarters · filed 2022-11-08 | 181.51K shares 10-Q · filed 2022-11-08 | 210.85K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 47.95K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | 92.02K shares 10-Q · filed 2022-08-10 | 121.36K shares derived: sum of 3 quarters · filed 2022-08-10 | 214.78K shares derived: sum of 4 quarters · filed 2022-08-10 |
| 2022-03-31 | 44.07K shares 10-Q · filed 2022-05-12 | 73.42K shares derived: sum of 2 quarters · filed 2022-05-12 | 166.83K shares derived: sum of 3 quarters · filed 2022-05-12 | 662.76K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 29.34K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 122.75K shares derived: sum of 2 quarters · filed 2022-03-15 | 618.69K shares derived: sum of 3 quarters · filed 2022-03-15 | 867.76K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 93.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 589.34K shares derived: sum of 2 quarters · filed 2021-11-10 | 838.42K shares 10-Q · filed 2021-11-10 | |
| 2021-06-30 | 495.93K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | 745.01K shares 10-Q · filed 2021-08-12 | ||
| 2021-03-31 | 249.07K shares 10-Q · filed 2021-05-17 | |||
| 2020-12-31 | 300.96K shares 10-K · filed 2021-03-12 | |||
| 2019-12-31 | 145.53K shares 10-K · filed 2021-03-12 | |||
| 2018-12-31 | 153.40K shares 10-K · filed 2021-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |